NTT Electronics Contributes Goldstone - Open Source Network OS for Disaggregated Coherent Transponders to the Telecom Infra Project
NTT Electronics, a leading provider of advanced components for optical communications systems including coherent optics and digital signal processors (DSPs), contributes the Goldstone Network Operating Software (NOS *1) for disaggregated coherent transponders to the Telecom Infra Project’s NOS Software Project hosted by the Open Optical and Packet Transport project group. Launched in February 2016, TIP was started with the goal of accelerating the pace of innovation in the telecom industry.
Goldstone utilizes many existing open source components which have been developed in Open Compute Project (OCP *2) and Telecom Infra Project (TIP *3) including Open Network Linux (ONL *4), SONiC *5, Switch Abstraction Interface (SAI *6) and Transponder Abstraction Interface (TAI *7) to provide a full-fledged open source solution. ONL is used as the base operating system and provides a wide range of open network device support. On top of ONL, Kubernetes *8 is employed to enable containerized application management, which realizes flexible and modular software composition. SONiC/SAI is deployed as a fleet of containers when the target hardware comprises Ethernet switch ASIC, whereas TAI is used when the target hardware has coherent transponder components. Because of its modular architecture, Goldstone can be extended to support networking devices, which don’t have Ethernet ASIC, but may include conventional transponders, ROADMs or amplifiers in the future.
Goldstone was originally started as a prototype NOS for Edgecore’s Cassini Platform by the proposal from NTT Electronics. This has led to a production deployment by mixi in Japan.
More than five industry partners are using Goldstone for evaluation on the Cassini platform.
It is also being incorporated in Wistron’s Galileo platform.
The NOS is planned to be contributed to TIP Open Optical Packet Transport (OOPT *9) group as an open source project. Goldstone is planned to be part of a live running demonstration at the TIP Summit 2019.
Quote from mixi, Inc.
“As the first operator who deployed Goldstone in production, mixi welcomes the contribution of Goldstone by NTT Electronics to foster more collaboration among the open networking industry. Goldstone brought us huge flexibility and control over our DCI connectivity which is critical for our services” Tatsuma Murase, CTO, mixi, Inc.
Quote from Edgecore
“Edgecore is pleased to be working with NTT Electronics and the broader industry community to enable disaggregated solutions with open packet transponders that will provide broader optical technology choices for network operators.” George Tchaparian, President and CEO, Edgecore Networks
Quote from Wistron
“Wistron is excited to have Goldstone in the open networking industry. Goldstone will accelerate the adaptation of the open disaggregated networking model and we believe it will become a viable solution together with our latest Galileo platform.” Arthur Chang, Sr. Technical Director, Wistron
*1 Network Operating System (NOS) : Operating system for a network device such as a router, switch or firewall.
*2 Open Compute Project (OCP) : The Open Compute Project (OCP) is a collaborative community focused on redesigning hardware technology to efficiently support the growing demands on compute infrastructure. In 2011, Facebook shared its designs with the public and launched the Open Compute Project and incorporated the Open Compute Project Foundation along with Intel, Rackspace, Goldman Sachs and Andy Bechtolsheim. (Reference: OCP web site: https://www.opencompute.org/)
*3 Telecom Infra Project (TIP) : The Telecom Infra Project (TIP) is a collaborative telecom community founded by Facebook and partners. Launched in February 2016, TIP was started with the goal of accelerating the pace of innovation in the telecom industry. TIP members include operators, suppliers, developers, integrators, startups, and other entities that have joined TIP to build new technologies and develop innovative approaches for deploying telecom network infrastructure. (Reference: TIP web site: https://telecominfraproject.com/)
*4 Open Network Linux (ONL) : Open Network Linux(ONL) is an open-source, foundational platform software layer for next-generation, modular NOS architecture on open networking hardware. ONL is a part of the Open Compute Project and is a component in a growing number of commercial NOS stacks and open source projects like CoRD & Stratum. (Reference: ONL web site : http://opennetlinux.org/)
*5 Software for Open Networking in the Cloud (SONiC) : Open source software developed by Microsoft, etc.. It dramatically enhances operations and management of network switches. (Reference: SONiC repository: http://azure.github.io/SONiC/)
*6 Switch Abstraction Interface (SAI) : The Switch Abstraction Interface (SAI) defines the API to provide a vendor-independent way of controlling forwarding elements, such as a switching ASIC, an NPU or a software switch in a uniform manner. (Reference: SAI repository: https://github.com/opencomputeproject/SAI)
*7 Transponder Abstraction Interface (TAI) : The Transponder Abstraction Interface (TAI) is the open API to provide a vendor-independent way of controlling coherent optical components. TAI has been developed under TIP OOPT group and NTT is leading the development. https://www.ntt.co.jp/news2018/1810e/181016c.html
*8 Kubernetes : Kubernetes is a portable, extensible, open-source platform for managing containerized workloads and services. Google open-sourced the Kubernetes in 2014. (Reference: Kubernetes web site : https://kubernetes.io/)
*9 Open Optical Packet Transport (OOPT) : The Open Optical & Packet Transport project group will define Dense Wavelength Division Multiplexing (DWDM) open packet transport architecture that triggers new innovation and avoids implementation lock-ins. Open DWDM systems include open line system & control, transponder & network management and packet-switch and router technologies. (Reference: TIP web site: https://telecominfraproject.com/oopt/)
About NTT Electronics
NTT Electronics (NEL) has been developing and commercializing optical communications devices since 1995. It has complete portfolio of optical and electronics products to cover the industry needs for 100G-and-beyond link systems, ROADM components and FTTH networks. For more information about NEL, visit https://www.ntt-electronics.com/en/.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20191112006191/en/
Contact information
Media Contacts:
Atul Srivastava, Chief Technical Officer
NTT Electronics America, Inc.
Email : pr@nel-america.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Hemato-Oncology Trials: AOP Health Presents New Results at Top Congress ASH7.12.2025 18:00:00 EET | Press release
AOP Health continues to advance its clinical research program in myeloproliferative neoplasms, a special group of rare blood cancers. The company, specialized in rare diseases, presented the results of two scientific investigations at the 67th American Society of Hematology Association (ASH) Annual Meeting 2025 held in Orlando, FL, USA. The results provide new insights in treatment strategies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251207587915/en/ Dr. Martin Steinhart, CEO AOP Health; Photo credit: AOP Health/Studio Koekart ROP-ET and BESREMI PASS One of the clinical studies, ROP-ET, examined the use of ropeginterferon alfa-2b in people with essential thrombocythemia (ET), a disease in which the body produces too many platelets. The trial, a prospective, multicenter, single-arm phase III study, investigated the safety and efficacy of ropeginterferon alfa-2b in ET patients unable to receive available cytoreductive th
CoMotion GLOBAL 2025 Launches in Riyadh: Global Mobility Leaders Unite in Saudi Capital to Chart Urban Future7.12.2025 14:00:00 EET | Press release
Riyadh is rapidly becoming one of the world's most ambitious urban mobility laboratories, where next-generation technologies move from blueprint to real-world deployment on city streets at unprecedented scale. CoMotion GLOBAL 2025, the world's most influential gathering of urban mobility leaders, opens today in Riyadh for a three-day summit bringing together innovators from Africa, Asia, Europe, the Americas, and the Middle East. Running December 7-9, the event will explore how electrification, autonomy, AI-enabled transport, and giga-project urbanism are reshaping cities worldwide. The summit will spotlight everything from high-performance EVs and breakthrough autonomous fleets to emerging-market transport solutions and new mobility models, demonstrating how the Kingdom is opening new pathways for global mobility leadership. Strategic Partnerships Powering the Summit CoMotion GLOBAL 2025 is hosted by the Saudi Conventions & Exhibitions General Authority (SCEGA), supported by key Saudi
Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67 th American Society of Hematology (ASH) Annual Meeting6.12.2025 16:30:00 EET | Press release
Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which Ono obtained exclusive global rights for the development and commercialization of sapablursen. “In the treatment of PV, phlebotomy and cytoreductive therapy are performed as treatments for preventing thrombosis. Phlebotomy is the most common treatment for PV, in which blood
Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera6.12.2025 16:30:00 EET | Press release
Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announce that new 52-week results from the pivotal Phase 3 VERIFY study evaluating rusfertide in patients with polycythemia vera (PV) will be presented in an oral presentation at the 67th American Society of Hematology (ASH) Annual Meeting and Exposition. These findings further reinforce rusfertide’s efficacy and safety and demonstrate durability of response, with 61.9% of patients continuously treated with rusfertide maintaining absence of phlebotomy eligibility from baseline to Week 52. “The 52-week data demonstrated the sustained efficacy of rusfertide, reducing the need for patients to receive phlebotomy while maintaining hematocrit control,” said Dr. Andrew T. Kuykendall, M.D., VERIFY Lead Investigator and Associate Member in the Department of Hematology at Moffitt Cancer Center. “The 32-week VERIFY primary results were already promising, and this deeper understanding of the durability of r
Vertex Presents New Data on CASGEVY ® , Including First-Ever Data in Children Ages 5-11 Years, at the American Society of Hematology Annual Meeting and Announces Plan for Global Regulatory Submissions6.12.2025 14:01:00 EET | Press release
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data from multiple studies demonstrating the clinical benefits of CASGEVY® (exagamglogene autotemcel) in people ages 5 years and older living with severe sickle cell disease (SCD) or transfusion-dependent beta thalassemia (TDT). The results, including the first presentation of clinical data from pivotal studies in children ages 5-11 years, and longer-term data from the pivotal studies of people with severe SCD and TDT ages 12 years and older, will be presented at the American Society of Hematology (ASH) Annual Meeting. CASGEVY is currently approved for eligible people ages 12 years and older with SCD or TDT in the United States, Great Britain, the European Union, the Kingdom of Saudi Arabia, the Kingdom of Bahrain, Kuwait, Qatar, Canada, Switzerland and the United Arab Emirates. “These results — the first clinical data ever presented on any genetic therapy for children ages 5-11 years with SCD — again demonstrate the tr
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
